TNFRSF9 and cancer: Recently, the role of 4‐1BB agonistic signaling in cancer immunotherapy has received great attention: the effect of 4-1BB stimulation by means of agonistic monoclonal anti-4‐1BB antibodies on cytolytic T-cell responses has been used to increase the potency of vaccines against cancers (58–60).